Difference between revisions of "WG6 Nonclinical - Standardization Roadmap"

From PHUSE Wiki
Jump to: navigation, search
(Conference Calls and Minutes)
(Conference Calls and Minutes)
Line 139: Line 139:
== Conference Calls and Minutes ==
== Conference Calls and Minutes ==
<!-- Add links to your Minutes pages by creating the page from the box and adding the name here. -->
<!-- Add links to your Minutes pages by creating the page from the box and adding the name here. -->
[[WG6 2012 Minutes]]
[[WG6 2013 Minutes]]
[[WG6 Tcon 1 Meeting minutes 04242012]]<br />
[[WG6 Tcon 1 Meeting minutes 04242012]]<br />

Revision as of 10:03, 14 May 2013

Roadmap for nonclinical data informatics standards

Welcome to the Wiki for the Roadmap for Nonclinical Data Informatics Accessibility Project, part of the of the FDA/PhUSE Computational Sciences Nonclinical Working Group. Learn more about the larger working group at Non-Clinical Road-map and Impacts on Implementation.

Overview & Scope


Need ID 0030. Currently, the SEND standard allows for the submission of general tox and carc studies in electronic standardized format. However, there are additional study types that are generally received that have not been standardized. There is a need to develop a strategy on how to prioritize, maximize, and transform standardization efforts. This plan should take into account resources, complexity, timeline and new approaches and technologies. Data gaps have been identified for many assessments, including Safety Pharm, Repro, Genetox, hERG, Animal Rule/MCM, Receptor Screen, and Device combination. Additionally, drug metadata can be better utilized so that, for example, Lot and Impurity information can be linked to study data, class, structure. Study Metadata represents another challenge. Information on protocol-related info + deviations, regulatory interpretation, sponsor interpretation, and regulatory information can be structured and linked so that information for a single study or across studies is more accessible.


Availability of useful electronic meta- and study data to enable more effective and efficient review of nonclinical data by both industry and regulatory reviewers. Data should be accessible to further investigate class effects and address regulatory science questions.


Identified Projects/Pilots/Activities

March 2012 - March 2013

  1. Communication of the CDISC SEND team roadmap/goals
  2. Identify elements that belong on the road map, including study types that need standardization and study metadata that enhance data utility. Identify potential roadblocks.
  3. Prioritize the elements from above and stratify them as projects for the immediate future versus longer term goals.
  4. A directory of knowledge on current standardization initiatives

March 2013 - March 2014

  1. Finish e-paper
  2. Standards Facilitation - Test space, open model concept, pilot, report, communication plan
  3. "How to Design a Domain"


March 2012 to March 2013
1 month

  • Convey CDISC SEND team roadmap/goals
  • Set up system for workgroup communications and forum on the WIKI

4 month

  • Identify study types that need standardization and elements that enhance data utility (i.e. tagging). Identify roadblocks.

7 month

  • Distribute survey to industry about priorities in nonclinical data"

9 month

  • Construct roadmap that prioritizes the standardization efforts and elements that integrate the data

March 2013 to March 2014
3 month

  • Finish e-paper

5 month

  • Characterize open forum, communication plan

7 month

  • Characterize test space, and testing process

9 month

  • Pilot run of test space with model (CNS model already established)

11 month

  • Report on pilot



  1. Prepare Wiki for the “call for participation” and establish means for group communication
  2. Communication of the CDISC SEND team roadmap/goals (via Wiki)
  3. List and prioritize the elements for the Standardization Roadmap including: the standardization of nonclinical study types, and elements that enhance data utility.
  4. Create a graphic which demonstrates the priorities and scope of the roadmap.


  1. Document current standardization efforts for nonclinical studies. (Wiki)
  2. Identify information gaps or challenges in current data (study types, exchange methods, standards, etc. Also consider integration with CMC and Clinical
  3. Characterize a view of optimal access to data
  4. Project: "Standards Facilitation"


March 2012 - March 2013

  • Developed a list of nonclinical study types and data elements for prioritization.
  • Graphical representation of roadmap for standardization priorities -
  • Presented poster, "Priorities in Nonclinical Data" at PhUSE 2013 meeting, results obtained from survey feedback

In-progress as of March 2013

  • e-paper containing prioritization
  • Directory of standardization initiatives

Participation needs

A vast number of stakeholders will be impacted by the transformation and implementation of data standards. As the impact will be broad, we need representation from people with diverse backgrounds to join and actively participate in this group. A broad representation from the pharmaceutical industry, contract research organisations, software vendors and other stakeholders in data standardisation and eventually regulatory submissions will ensure the most complete and robust picture for the industry and the regulators to align to going forward.

  • Participants may have backgrounds which include (but are not limited to)
    • Pharmacologists/Toxicologists
    • Pathologists
    • Pharmacokineticists
    • Informatics and database specialists
    • Those with experience in data standardization
    • Those implementing data standards

Member Commitment

  • Teleconferences will require active participation for approximately 1 hour every two weeks. Our open forum needs your creative and innovative ideas.
  • Projects will require time and effort outside of general teleconferences. Time commitments will vary but are likely to take several hours per month.
  • Ongoing email/phone correspondences and additions to the Wiki are essential to developing these projects.
  • Members contribute to Wiki content, meeting proceedings, and presentations that result from the group's effort.


  • Teleconference are held once every two weeks (Tuesdays at 10 am EST) starting on April 24th, 2012.
    • T-con details will be shared among members
  • Quarterly updates to overall WG.
  • Our Wiki page will serve as a resource for developing content and archiving meeting minutes.

*Contact Gitte Frausing (gttf@novonordisk.com) or Bob Dorsam (robert.dorsam@fda.hhs.gov) with any questions or inquiries about joining the working group

Work Group Participants

Gitte Frausing, Novo Nordisk (co-lead), gttf@novonordisk.com

Bob Dorsam, FDA (co-lead), robert.dorsam@fda.hhs.gov

Deborah Sholtes, FDA

Lou Ann Kramer, Eli Lilly

Lynda Sands, GlaxoSmithKline

Debra Oetzman, Covance

Sarah Obbers, Janssen Research & Development
Anisa Scott, SAS Institute, Inc.
Rick Thompson, Janssen Research & Development
Donna Danduone, Instem

Former members:

Alain Nanzer, Roche
Jerker Ringstrom, SixSteps AB

Geoff Mann, SAS Institute

John Anderson, Novo Nordisk

Natalia Smeljanski, Merck

Conference Calls and Minutes

WG6 2012 Minutes WG6 2013 Minutes

WG6 Tcon 1 Meeting minutes 04242012
WG6 Tcon2 Meeting minutes 05082012
WG6 Tcon3 Meeting minutes 06052012
WG6 Tcon5 Meeting minutes 07022012
WG6 Tcon6 Meeting minutes 07024012
WG6 Tcon7 Meeting minutes 07312012
WG6 Tcon6 Meeting minutes 08152012
WG6 Tcon9 Meeting minutes 08292012
WG6 Tcon11 Meeting minutes 08292012
WG6 Tcon12 Meeting minutes 10092012
WG6 Tcon13 Meeting minutes 10232012
WG6 Tcon15 Meeting minutes 11202012
WG6 Tcon16 Meeting minutes 12052012
WG6 Roadmap TconMeeting minutes 03282013
Nonclinical Standards Roadmap TconMeeting minutes 04232013
Nonclinical Standards Roadmap TconMeeting minutes 05072013



FDA comments are an informal communication and represent the individual's best judgment. These comments do not bind or obligate FDA. The contents of this wiki are from the individual contributors and do not necessarily reflect the view and/or policies of the Food and Drug Administration, the employers of the individuals involved or any of their staff.

Last revision by DanBoisvert,05/14/2013